Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: a pilot study
- 531 Downloads
Trichotillomania is characterized by repetitive pulling causing noticeable hair loss. Pharmacological treatment data for trichotillomania are limited.
Dronabinol appears to reduce the exocitotoxic damage caused by glutamate release in the striatum and offers promise in reducing compulsive behavior.
Fourteen female subjects (mean age = 33.3 ± 8.9) with DSM-IV trichotillomania were enrolled in a 12-week open-label treatment study of dronabinol (dose ranging from 2.5–15 mg/day). The primary outcome measure was change from baseline to study endpoint on the Massachusetts General Hospital Hair Pulling Scale (MGH-HPS). In order to evaluate effects on cognition, subjects underwent pre- and post-treatment assessments using objective computerized neurocognitive tests. Data were collected from November 2009 to December 2010.
Twelve of the 14 subjects (85.7%) completed the 12-week study. MGH-HPS scores decreased from a mean of 16.5 ± 4.4 at baseline to 8.7 ± 5.5 at study endpoint (p = 0.001). Nine (64.3%) subjects were “responders” (i.e., ≥35% reduction on the MGH-HPS and “much or very much improved” Clinical Global Impression scale). The mean effective dose was 11.6 ± 4.1 mg/day. The medication was well-tolerated, with no significant deleterious effects on cognition.
This study, the first to examine a cannabinoid agonist in the treatment of trichotillomania, found that dronabinol demonstrated statistically significant reductions in trichotillomania symptoms, in the absence of negative cognitive effects. Pharmacological modulation of the cannabinoid system may prove useful in controlling a range of compulsive behaviors. Given the small sample and open-label design, however larger placebo-controlled studies incorporating cognitive measures are warranted.
KeywordsCannabinoid Impulsivity Cognition CANTAB CB1 CB2
This study was funded by internal research funds.
Disclosures/conflicts of interest
Dr. Grant has received research grants from NIMH, NIDA, National Center for Responsible Gaming and its affiliated Institute for Research on Gambling Disorders, and Forest Pharmaceuticals. Dr. Grant receives yearly compensation from Springer Publishing for acting as Editor-in-Chief of the Journal of Gambling Studies. Dr. Grant has received royalties from Oxford University Press, American Psychiatric Publishing, Inc., Norton Press, and McGraw Hill. Mr. Odlaug has received royalties from Oxford University Press. Dr. Chamberlain has consulted for Cambridge Cognition, P1Vital, and Shire Pharmaceuticals. Dr. Kim reports no financial or other relationship relevant to the subject of this article.
- American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, D.C., text revisionGoogle Scholar
- Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, Morales JO, Murphy R, Powderly W, Plasse TF, Mosdell KW, Shepard KV (1997) Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 14:7–14PubMedCrossRefGoogle Scholar
- Cambridge Cognition Limited (2006) CANTABeclipse, version 3. Cambridge Cognition Limited, CambridgeGoogle Scholar
- Chamberlain SR, Robbins TW, Winder-Rhodes S, Müller U, Sahakian BJ, Blackwell AD, Barnett JH (2010b). Translational approaches to frontostriatal dysfunction in attention-deficit/hyperactivity disorder using a computerized neuropsychological battery. Biol Psychiatry. doi: 10.1016/j.biopsych.2010.08.019
- Christenson GA, Mansueto CS (1999) Trichotillomania: descriptive characteristics and phenomenology. In: Stein DJ, Christianson GA, Hollander E (eds) Trichotillomania. American Psychiatric Press, Washington, D.C., pp 1–41Google Scholar
- First MB, Spitzer RL, Gibbon M, Williams JBW (1995) Structured Clinical Interview for DSM-IV-Patient Edition (SCID-I/P, Version 2.0). Biometrics Research Department, New York State Psychiatric Institute, New YorkGoogle Scholar
- Flessner CA, Woods DW, Franklin ME, Cashin SE, Keuthen NJ, Trichotillomania Learning Center-Scientific Advisory Board (TLC-SAB) (2008) The Milwaukee Inventory for Subtypes of Trichotillomania-Adult Version (MIST-A): development, exploratory factor analysis, and psychometric properties. J Psychopathol Behav Assess 30:20–30CrossRefGoogle Scholar
- Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education and Welfare publication (ADM). National Institute of Mental Health, Rockville, pp 76–338Google Scholar
- Hunault CC, Mensinga TT, Böcker KB, Schipper CM, Kruidenier M, Leenders ME, de Vries I, Meulenbelt J (2009) Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC). Psychopharmacology (Berl) 204:85–94CrossRefGoogle Scholar
- Lezak MD, Howieson DB, Loring DW et al (2004) Neuropsychological Assessment. Oxford University Press, New YorkGoogle Scholar
- Sheehan DV (1983) The anxiety disease. Scribner’s, New YorkGoogle Scholar
- Woods DW, Flessner CA, Franklin ME, Keuthen NJ, Goodwin RD, Stein DJ, Walther MR, Trichotillomania Learning Center-Scientific Advisory Board (2006b) The Trichotillomania Impact Project (TIP): exploring phenomenology, functional impairment, and treatment utilization. J Clin Psychiatry 67:1877–1888PubMedCrossRefGoogle Scholar